Project Grant R01AI190043
- Federal Project Grant Award Summary Cornell University's Office of Sponsored Programs received a $743,943 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 5, 2026, through April 30, 2031. This research initiative focuses on advancing the understanding and engineering of antimicrobial peptides (AMPs) as potential therapeutic compounds to combat opportunistic...
- Federal Grant Award Summary Cornell University received a $219,852 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 1, 2026 through April 28, 2028. This exploratory research initiative investigates the bacterial endosymbiont accommodation (BEA) program in early-divergent mucoromycete fungi, with the objective of elucidating the developmental and regulatory...
- Federal Grant Award Summary Cornell University received a $291,491 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective April 1, 2026, through January 31, 2031. The award supports fundamental research focused on understanding autolysin function in gram-negative bacterial growth and morphogenesis. Specifically, the research aims to elucidate how endopeptidases (EPs) and lytic...
- Federal Project Grant Award Summary Cornell University's Office of Sponsored Programs received a $746,602 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2030. The award supports investigator-initiated biomedical research to develop novel therapeutics for tuberculosis (TB) treatment by stimulating bacterial cyclic adenosine monophosphate...
- Federal Grant Award Summary Cornell University, through its Office of Sponsored Programs, received a $591,368 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 11, 2025, with a completion date of July 31, 2030. The award supports fundamental research aimed at understanding the epigenetic regulation of natural killer (NK) cell memory, with particular focus on...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $1.67 million Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 11, 2025, with a completion date of May 31, 2030. The award funds research investigating the molecular mechanisms by which Enterococcus faecalis transitions from a benign commensal bacterium to a pathogenic organism capable of...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $392,714 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 1, 2025 through July 31, 2030. The award supports research and development of lipid nanoparticles (LNPs) designed to enhance endosomal escape and reduce reactogenicity—key barriers to effective nucleic acid-lipid...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a $2.8 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 4, 2026, with a completion date of January 31, 2030. This research grant supports biomedical investigation into post-transcriptional regulation mechanisms controlling pathogenic T helper 17 (Th17) cell function, with...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a Project Grant of $238,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 1, 2025, with completion scheduled for August 31, 2027. The research project, titled "Embryonic Origins of T Cells," addresses fundamental gaps in understanding T lymphocyte development and function. The grant...
- Federal Project Grant Award Summary Award Details: The National Institute of Allergy and Infectious Diseases (NIAID) awarded Weill Medical College of Cornell University a Project Grant valued at $254,250 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award was obligated on August 7, 2025, with an ultimate completion date of July 31, 2027, and performance conducted in New York. Products and Services: The grant funds research to develop and test proteolysis-targeting...
Cornell University's Office of Sponsored Programs received a $408,133 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 7, 2026, with completion scheduled for April 30, 2031. The project, "A Systems Approach to Understanding Beta Lactam Antibiotic Mechanism of Action," will deliver comprehensive research services and scientific findings to advance understanding of how beta-lactam antibiotics (penicillin and related compounds) kill bacteria. This fundamental research addresses a critical gap in antimicrobial science despite decades of intensive investigation. The research will produce novel analytical tools, bacterial model systems, and integrated mechanistic models that characterize beta-lactam-induced bacterial cell wall degradation. Specifically, Cornell will develop and deploy a peptidoglycan architecture analysis pipeline to quantitatively assess cell wall turnover in high-throughput fashion and establish new bacterial model systems that permit structural analysis during antibiotic-induced degradation. Deliverables will include comprehensive data on downstream consequences of beta-lactam exposure, quantified contributions of specific autolysins (cell wall-degrading enzymes) to the cell wall turnover process, identified pathways and environmental conditions modulating antibiotic mechanism of action, and a functionally integrated model encompassing environmental cues, metabolic functions, and autolytic potential. These research outputs are intended to fuel subsequent development of novel antimicrobial therapeutics to address antibiotic-resistant pathogens.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $408.1k | 5/11/26 |